Known and less well-known comorbidities in axial spondyloarthritis: what are we overlooking? Results from the SPARTAKUS cohort
axSpA is linked to several comorbidities, whereas no difference was observed between nr-axSpA and r-axSpA. Potential causes of enhanced comorbidity include long-standing inflammation and therapy side-effects (including from NSAIDs/glucocorticoids), both to be considered when aiming to optimize axSpA treatment.
Authors
- Anna Jöud (ORCID: https://orcid.org/0000-0001-7192-4911)
- J. Sagard (ORCID: https://orcid.org/0000-0001-7227-0665)
- Johan K. Wallman (ORCID: https://orcid.org/0000-0002-4915-2924)
- Elisabeth Mogård (ORCID: https://orcid.org/0000-0002-5706-203X)
- Mats Geijer (ORCID: https://orcid.org/0000-0003-0529-7723)
- Elisabet Lindqvist (ORCID: https://orcid.org/0000-0002-9937-6352)
- Tor Olofsson (ORCID: https://orcid.org/0000-0002-9919-4487)
Institutions
- National Academy of Medicine (US)
- Lund University (SE)
- Skåne University Hospital (SE)
- University of Gothenburg (SE)
Publication Details
- Journal
- Scandinavian Journal of Rheumatology
- Published
- 2025-09-01
- DOI
- https://doi.org/10.1080/03009742.2025.2525635
- Primary Topic
- Spondyloarthritis Studies and Treatments
- Type
- article
- Field-Weighted Citation Impact
- 0.00
Funders
- Anna-Greta Crafoords Stiftelse för Reumatologisk Forskning
- Reumatikerförbundet
- Skånes universitetssjukhus